TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
Acute oncology: new immunotherapy guidelines
What is the deciding factor in a clinician’s choice of drug?
Current trials in the treatment of melanoma